Floatz logo

Nivolumab

EGFR Activating Mutation

University of Washingtonmonoclonal_antibodyPhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the EGFR Activating Mutation cohort.

Asset / SponsorPhaseRating
Carboplatin
Juntendo University
Phase 4BB
Osimertinib
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
ty-9591
TYK Medicines, Inc
Phase 3BB
Gefetinib
Sichuan University
Phase 4BB
Famitinib
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB

View all 21 →

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →